Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crystal Pharmatech and Particle Sciences Form CRO Partnership

Published: Wednesday, February 27, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Two companies bring intelligent, optimal solutions for insoluble drugs to innovative pharmaceutical companies.

Crystal Pharmatech announced a partnership with Particle Sciences, one of the world's leading contract drug development companies focused on the formulation and support of advanced drug delivery solutions. The partnership, one of many that Crystal Pharmatech is forging with research driven organizations, combines a level of expertise previously not available to CRO's that will increase the success rate for the development of insoluble pharmaceutical compounds. Both will now offer clients an optimal solution for developing low solubility pharmaceutical compounds.

Over the past five years, approximately 65% of pharmaceutical compounds under development have been sparingly soluble to practically insoluble in water. This has led to the need for more innovative formulation and solubilization techniques. As scientific complexity of drug development increases, finding the appropriate CRO to bring about the optimal development path for both drug substance (API) and drug product (formulation) is of utmost importance. Crystal Pharmatech, a preferred provider among innovator pharmaceutical companies, has extensive experience selecting the appropriate solid phase of a wide range of compounds. The company has a proven track record among its customers to provide fundamental material property evaluation, in addition to screening, evaluating and selecting the optimal form for pharmaceutical development. Particle Sciences brings over two decades of experience in formulating active pharmaceutical ingredients (APIs) and multiple delivery/formulation formats. In addition, the company is able to identify common obstacles in drug product development and provide a resource of delivery technologies to address these obstacles.

“Whether the best way to develop your product is a co-crystal or nano-suspension depends on the material properties of your drug and the delicate interplay between API and formulation development," explains Alex Chen, CEO of Crystal Pharmatech. Robert Lee, Vice President, Pharmaceutical Development at Particle Sciences adds, “Often times, a client will work with a CRO to find a path forward for API development, only to realize that the chosen path is unacceptable for formulation development and, as a result, the project goes over the allocated time and budget.” Both Crystal Pharmatech and Particle Sciences vetted a number of potential partners prior to aligning with each other and each company will utilize the other’s core expertise to seamlessly offer clients the optimal program for their drug candidates.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!